443 related articles for article (PubMed ID: 35109664)
41. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data.
Harkus U; Wankell M; Palamuthusingam P; McFarlane C; Hebbard L
Semin Cancer Biol; 2022 Nov; 86(Pt 3):799-815. PubMed ID: 35065242
[TBL] [Abstract][Full Text] [Related]
42. Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice.
Pinter M; Scheiner B; Pinato DJ
Lancet Gastroenterol Hepatol; 2023 Aug; 8(8):760-770. PubMed ID: 37327807
[TBL] [Abstract][Full Text] [Related]
43. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups.
Pinter M; Scheiner B; Peck-Radosavljevic M
Gut; 2021 Jan; 70(1):204-214. PubMed ID: 32747413
[TBL] [Abstract][Full Text] [Related]
44. Immunostimulatory monoclonal antibodies for hepatocellular carcinoma therapy. Trends and perspectives.
Mazzolini GD; Malvicini M
Medicina (B Aires); 2018; 78(1):29-32. PubMed ID: 29360073
[TBL] [Abstract][Full Text] [Related]
45. Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma.
Ji JH; Ha SY; Lee D; Sankar K; Koltsova EK; Abou-Alfa GK; Yang JD
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108802
[TBL] [Abstract][Full Text] [Related]
46. Microecological regulation in HCC therapy: Gut microbiome enhances ICI treatment.
Liu X; Li S; Wang L; Ma K
Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167230. PubMed ID: 38734322
[TBL] [Abstract][Full Text] [Related]
47. Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy.
Rizzo A; Ricci AD; Brandi G
Future Oncol; 2021 Mar; 17(7):755-757. PubMed ID: 33508960
[No Abstract] [Full Text] [Related]
48. Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019.
Tovoli F; Casadei-Gardini A; Benevento F; Piscaglia F
Dig Liver Dis; 2019 Aug; 51(8):1067-1073. PubMed ID: 31208929
[TBL] [Abstract][Full Text] [Related]
49. Development of a TMErisk model based on immune infiltration in tumour microenvironment to predict prognosis of immune checkpoint inhibitor treatment in hepatocellular carcinoma.
Yan ZJ; Yu CT; Chen L; Wang HY
Brief Bioinform; 2023 Mar; 24(2):. PubMed ID: 36882021
[TBL] [Abstract][Full Text] [Related]
50. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
[TBL] [Abstract][Full Text] [Related]
52. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.
Sangro B; Chan SL; Meyer T; Reig M; El-Khoueiry A; Galle PR
J Hepatol; 2020 Feb; 72(2):320-341. PubMed ID: 31954495
[TBL] [Abstract][Full Text] [Related]
53. Immunotherapy in older patients with hepatocellular carcinoma.
Lyu N; Yi JZ; Zhao M
Eur J Cancer; 2022 Feb; 162():76-98. PubMed ID: 34954439
[TBL] [Abstract][Full Text] [Related]
54. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma.
Wang Y; Jiang M; Zhu J; Qu J; Qin K; Zhao D; Wang L; Dong L; Zhang X
Biomed Pharmacother; 2020 Dec; 132():110797. PubMed ID: 33068935
[TBL] [Abstract][Full Text] [Related]
55. Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma.
Lee BM; Seong J
World J Gastroenterol; 2021 Mar; 27(10):919-927. PubMed ID: 33776363
[TBL] [Abstract][Full Text] [Related]
56. Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma.
Chen X; Kou L; Xie X; Su S; Li J; Li Y
Immunology; 2024 May; 172(1):21-45. PubMed ID: 38214111
[TBL] [Abstract][Full Text] [Related]
57. Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors.
Abenavoli L; Montori M; Svegliati Baroni G; Argenziano ME; Giorgi F; Scarlata GGM; Ponziani F; Scarpellini E
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629716
[No Abstract] [Full Text] [Related]
58. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
[TBL] [Abstract][Full Text] [Related]
59. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.
Shi J; Liu J; Tu X; Li B; Tong Z; Wang T; Zheng Y; Shi H; Zeng X; Chen W; Yin W; Fang W
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101942
[TBL] [Abstract][Full Text] [Related]
60. Neoadjuvant systemic therapy for hepatocellular carcinoma.
Chick RC; Ruff SM; Pawlik TM
Front Immunol; 2024; 15():1355812. PubMed ID: 38495884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]